Fagron Compounds Recalls Bevacizumab Injection Over Sterility Risk
Fagron Compounding Services recalled 109,320 syringes of bevacizumab (Avastin) on August 29, 2025. The recall follows a lack of assurance of sterility, posing a high health risk. Consumers and healthcare providers should stop using the product immediately.